Form 8-K

8-K — Prestige Consumer Healthcare Inc.

Accession: 0001295947-26-000055

Filed: 2026-11-05

Period: 2026-11-05

CIK: 0001295947

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Results of Operations and Financial Condition

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — pbh-20261105.htm (Primary)

EX-99.1 (exhibit991fy27-q2earningsr.htm)

EX-99.2 (exhibit992pbh_fy27xq2.htm)

GRAPHIC (exhibit992pbh_fy27xq2001.jpg)

GRAPHIC (exhibit992pbh_fy27xq2002.jpg)

GRAPHIC (exhibit992pbh_fy27xq2003.jpg)

GRAPHIC (exhibit992pbh_fy27xq2004.jpg)

GRAPHIC (exhibit992pbh_fy27xq2005.jpg)

GRAPHIC (exhibit992pbh_fy27xq2006.jpg)

GRAPHIC (exhibit992pbh_fy27xq2007.jpg)

GRAPHIC (exhibit992pbh_fy27xq2008.jpg)

GRAPHIC (exhibit992pbh_fy27xq2009.jpg)

GRAPHIC (exhibit992pbh_fy27xq2010.jpg)

GRAPHIC (exhibit992pbh_fy27xq2011.jpg)

GRAPHIC (exhibit992pbh_fy27xq2012.jpg)

GRAPHIC (exhibit992pbh_fy27xq2013.jpg)

GRAPHIC (exhibit992pbh_fy27xq2014.jpg)

GRAPHIC (exhibit992pbh_fy27xq2015.jpg)

GRAPHIC (exhibit992pbh_fy27xq2016.jpg)

GRAPHIC (exhibit992pbh_fy27xq2017.jpg)

GRAPHIC (exhibit992pbh_fy27xq2018.jpg)

GRAPHIC (exhibit992pbh_fy27xq2019.jpg)

GRAPHIC (exhibit992pbh_fy27xq2020.jpg)

GRAPHIC (exhibit992pbh_fy27xq2021.jpg)

GRAPHIC (exhibit992pbh_fy27xq2022.jpg)

GRAPHIC (exhibit992pbh_fy27xq2023.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: pbh-20261105.htm · Sequence: 1

pbh-20261105

0001295947false00012959472026-11-052026-11-05

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_______________________

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): November 5, 2026

PRESTIGE CONSUMER HEALTHCARE INC.

(Exact Name of Registrant as Specified in Charter)

Delaware 001-32433 20-1297589

(State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)

660 White Plains Road, Tarrytown, New York 10591

(Address of Principal Executive Offices) (Zip Code)

(914) 524-6800

(Registrant's telephone number, including area code)

(Former Name or Former Address, if Changed Since Last Report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered

Common stock, par value $0.01 per share PBH New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

☐

Item 2.02 Results of Operations and Financial Condition.

On November 5, 2026, Prestige Consumer Healthcare Inc. (the “Company”) announced financial results for the fiscal quarter and six months ended September 30, 2026. A copy of the press release announcing the Company's earnings results for the fiscal quarter and six months ended September 30, 2026 is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Item 7.01 Regulation FD Disclosure.

On November 5, 2026, representatives of the Company began making presentations to investors regarding the Company's financial results for the quarter and six months ended September 30, 2026 using slides attached to this Current Report on Form 8-K as Exhibit 99.2 (the “Investor Presentation”) and incorporated herein by reference. The Company expects to use the Investor Presentation, in whole or in part, and possibly with modifications, in connection with presentations to investors, analysts and others during the fiscal year ended March 31, 2027.

By furnishing the information contained in this Item 7.01, the Company makes no admission as to the materiality of any information that is required to be disclosed solely by reason of Regulation FD.

The information contained in the Investor Presentation is summary information that is intended to be considered in the context of the Company's Securities and Exchange Commission (“SEC”) filings and other public announcements that the Company may make, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in this report, although it may do so from time to time as its management believes is warranted. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosure.

The information presented in Items 2.02 and 7.01 of this Current Report on Form 8-K and Exhibits 99.1 and 99.2 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, unless the Company specifically states that the information is to be considered “filed” under the Exchange Act or specifically incorporates it by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Description

99.1

Press Release dated November 5, 2026 announcing the Company's financial results for the fiscal quarter and six months ended September 30, 2026 (furnished only).

99.2

Investor Presentation in use beginning November 5, 2026 (furnished only).

104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: November 5, 2026 PRESTIGE CONSUMER HEALTHCARE INC.

By: /s/ Christine Sacco

Christine Sacco

Chief Financial Officer & Chief Operating Officer

EX-99.1

Filename: exhibit991fy27-q2earningsr.htm · Sequence: 2

Document

Exhibit 99.1

Prestige Consumer Healthcare Inc. Reports Fiscal 2027 Second Quarter Results

•Q2 Revenue of $336.3 million, up 22.7% versus prior year

•Q2 Diluted EPS of $0.53; Adjusted Diluted EPS of $1.13, compared to prior year Adjusted Diluted EPS of $1.07

•The Breathe Right® portfolio and LaCorium acquisitions performed as expected in first full quarter of ownership

•Adjusting guidance outlook range to $1,280 to $1,290 million in revenue, $4.48 to $4.55 in Adjusted Diluted EPS

TARRYTOWN, N.Y.--(GLOBE NEWSWIRE)-November 5, 2026-- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its second quarter and first half fiscal 2027 ended September 30, 2026.

“We were pleased with our second quarter and first half revenue and EPS performance, driven by continued strength in our leading brands and strong early contributions from the Breathe Right® portfolio and LaCorium acquisitions that closed in June and July, respectively. Our portfolio performed in line with our expectations, with strong consumption growth across channels including eCommerce. This translated into strong mid-single-digit earnings growth and sets us up for continued strong free cash flow moving forward,” said Ron Lombardi, Chief Executive Officer of Prestige Consumer Healthcare.

Second Fiscal Quarter Ended September 30, 2026

Reported revenues in the second quarter of fiscal 2027 of $336.3 million increased 22.7% from $274.1 million in the second quarter of fiscal 2026, but decreased 1.6% excluding the impacts of foreign currency and a $65.1 million contribution from the acquisition of the Breathe Right® portfolio and LaCorium. The organic revenue performance versus the prior year comparable period reflected the expected headwind associated with order timing in Q1 and a decline in Clear Eyes®.

Reported net income for the second quarter of fiscal 2027 totaled $25.3 million, or $0.53 in diluted earnings per share, compared to $42.2 million, or $0.86 in diluted earnings per share, for the comparable period of fiscal 2026. On an adjusted non-GAAP basis, second quarter fiscal 2027 net income totaled $53.8 million, or $1.13 in diluted earnings per share, versus $52.5 million in net income and $1.07 in diluted earnings per share in the prior year comparable period.

Adjustments to net income in the second quarter of fiscal 2027 included certain costs associated with acquisitions including integration, transition, purchase accounting, legal and various other costs, such as costs associated with improving and optimizing the acquired Pillar5 facility for increases in long-term capacity, a loss on extinguishment of debt, associated tax adjustments and a normalized tax adjustment pertaining to the establishment of a valuation allowance against deferred tax assets. The adjustment to the second quarter of fiscal 2026 relates to a discrete tax item pertaining to establishing a taxable presence in a new state.

Six Months Ended September 30, 2026

Reported revenues for the first six months of fiscal 2027 totaled $602.0 million and compared to revenues of $523.6 million for the first six months of fiscal 2026. Revenues increased 15.0% versus the prior year comparable period and 0.7% excluding the impact of foreign currency and a $71.0 million contribution from the acquisition of the Breathe Right® portfolio and LaCorium. The organic revenue

increase for the first six months reflected increased demand across the broad portfolio which more than offset a decline in Clear Eyes®.

Reported net income for the first six months of fiscal 2027 totaled $54.5 million versus the prior year comparable period net income of $89.7 million. Non-GAAP adjusted net income for the first six months of fiscal 2027 totaled $100.3 million versus the prior year comparable period’s adjusted net income of $99.9 million. Diluted earnings per share were $1.14 for the first six months of fiscal 2027 compared to $1.81 per share in the prior year comparable period. Non-GAAP adjusted diluted earnings per share of $2.11 for the first six months of fiscal 2027 increased over the prior year comparable period’s adjusted diluted earnings per share of $2.02.

Adjustments to net income in the first six months of fiscal 2027 included certain costs associated with acquisitions including integration, transition, purchase accounting, legal and various other costs, such as costs associated with improving and optimizing the acquired Pillar5 facility for increases in long-term capacity, as well as a loss on extinguishment of debt, associated tax adjustments, and a normalized tax adjustment pertaining to the establishment of a valuation allowance against deferred tax assets. The adjustment to the first six months of fiscal 2026 relates to a discrete tax item pertaining to establishing a taxable presence in a new state.

Free Cash Flow and Balance Sheet

The Company's net cash provided by operating activities for the first six months of fiscal 2027 was $108.7 million, compared to $136.5 million during the prior year comparable period. Non-GAAP adjusted free cash flow in the first six months of fiscal 2027 was $123.0 million compared to $133.6 million in the prior year comparable period.

The Company's net debt position as of September 30, 2026 was approximately $2 billion. On July 15, 2026, the Company issued $400 million of new 6.25% senior notes due July 2034, which replaced the same principal of senior notes previously due in fiscal 2028.

Segment Review

North American OTC Healthcare: Segment revenues of $271.8 million for the second quarter fiscal 2027 increased 17.8% compared to the prior year comparable quarter's segment revenues of $230.8 million. The revenue increase was driven by a $47.5 million contribution from the acquisitions of the Breathe Right® portfolio and LaCorium, partially offset by lower base business sales associated with accelerated order timing in first quarter fiscal 2027.

For the first six months of the current fiscal year, reported revenues for the North American OTC segment were $498.0 million, which compared to $443.3 million in the prior year comparable period.

The revenue increase was primarily driven by a $52.0 million contribution from the acquisitions of the Breathe Right® portfolio and LaCorium, as well as higher CompoundW® and TheraTears® sales.

International OTC Healthcare: Fiscal second quarter 2027 segment revenues of $64.5 million increased 48.7% compared to $43.4 million reported in the prior year comparable period. The revenue performance was primarily driven by a $17.6 million contribution from the acquisitions of the Breathe Right® portfolio and LaCorium, as well as double-digit sales growth for Hydralyte®.

For the first six months of the current fiscal year, reported revenues for the International OTC Healthcare segment were $104.0 million, an increase of approximately 30% over the prior year comparable period’s revenues of $80.3 million. Strong revenue growth was primarily driven by a $19.0

million contribution from the acquisitions of the Breathe Right® portfolio and LaCorium, as well as continued growth for Hydralyte®.

Updated Fiscal 2027 Outlook

Ron Lombardi, Chief Executive Officer, stated, "We are updating our fiscal 2027 outlook for revenues to $1,280 million to $1,290 million and adjusted diluted EPS of $4.48 to $4.55 primarily to reflect recent variability in Clear Eyes® production at Pillar5, which is expected to reduce product availability and revenue in the second half. While supply remains limited for Clear Eyes®, we continue to invest in our Pillar5 production site with the intent of delivering consistent quality output that generates long-term growth for the brand."

"It's important to note that our outlook for the remainder of the portfolio is unchanged, with the base business delivering growth and our recent acquisitions on track to deliver sales and profit consistent with our prior guidance. Against a challenging consumer environment, this is a testament to our trusted brands and diversified business model."

“We remain confident in our business, the strategic investments we have made over the past twelve months, and our medium-term outlook for approximately 10% annual revenue growth, approximately 8% annual EPS growth, and nearly $900 million of aggregate free cash flow over the next three years. The acquisitions of Breathe Right® and LaCorium provide attractive long-term growth opportunities as we integrate these brands into our portfolio. The acquisition of Pillar5 will provide vertical integration of our eye care supply chain and an important platform for continued investment in capacity, reliability and long-term growth. Together, these investments further strengthen our diversified portfolio and financial profile while supporting strong free cash flow, debt reduction and future capital deployment,” Mr. Lombardi concluded.

Previous Fiscal 2027 Outlook

Current Fiscal 2027 Outlook

Revenue

$1,290 to $1,315 million $1,280 to $1,290 million

Organic Revenue Growth

+1.0% to +3.0% ~ Flat

Adjusted Diluted E.P.S.

$4.55 to $4.65 $4.48 to $4.55

Adjusted Free Cash Flow

$270 million or more $265 million or more

Second Quarter Fiscal 2027 Conference Call, Accompanying Slide Presentation and Replay

The Company will host a conference call to review its second quarter and first half fiscal 2027 results today, November 5, 2026 at 8:30 a.m. ET. The Company provides a live Internet webcast, a slide presentation to accompany the call, as well as an archived replay, all of which can be accessed from the Investor Relations page of the Company's website at http://www.prestigeconsumerhealthcare.com. To participate in the conference call via phone, participants may register for the call here to receive dial-in details and a unique pin. While not required, it is recommended to join 10 minutes prior to the event start. The slide presentation can be accessed from the Investor Relations page of the Company’s website by clicking on Webcasts and Presentations.

A conference call replay will be available for approximately one week following completion of the live call and can be accessed on the Company’s Investor Relations page.

Non-GAAP and Other Financial Information

In addition to financial results reported in accordance with generally accepted accounting principles (GAAP), we have provided certain non-GAAP financial information in this release to aid investors in understanding the Company's performance. Each non-GAAP financial measure is defined and reconciled to its most closely related GAAP financial measure in the “About Non-GAAP Financial Measures” section at the end of this earnings release.

Note Regarding Forward-Looking Statements

This news release contains "forward-looking statements" within the meaning of the federal securities laws that are intended to qualify for the Safe Harbor from liability established by the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" generally can be identified by the use of forward-looking terminology such as "guidance," "outlook," "may," "will," "would," “believe,” “set up,” "expect," “on track,” "anticipate,” “positioned,” or "continue" (or the negative or other derivatives of each of these terms) or similar terminology. The "forward-looking statements" include, without limitation, statements regarding the Company's future operating results including revenues, organic growth, adjusted diluted earnings per share, and adjusted free cash flow; supply of Clear Eyes® and return to category leadership; the expected impact of Breathe Right® and LaCorium Health acquisitions on the Company’s sales and profit; the Company’s ability to rapidly reduce debt; and the Company’s ability to manage through the current environment through its business strategy and diverse product portfolio. These statements are based on management's estimates and assumptions with respect to future events and financial performance and are believed to be reasonable, though are inherently uncertain and difficult to predict. Actual results could differ materially from those expected as a result of a variety of factors, including the impact of business and economic conditions, including as a result of evolving U.S. and international tariffs, labor shortages, inflation and geopolitical instability, consumer trends, the impact of the Company’s advertising and marketing and new product development initiatives, customer inventory management initiatives and ordering patterns, fluctuating foreign exchange rates, competitive pressures, and the ability of the Company’s manufacturing operations and third party manufacturers and logistics providers and suppliers to meet demand for its products and to avoid inflationary cost increases and disruption as a result of labor shortages. A discussion of other factors that could cause results to vary is included in the Company's Annual Report on Form 10-K for the year ended March 31, 2026 and other periodic reports filed with the Securities and Exchange Commission.

About Prestige Consumer Healthcare Inc.

Prestige Consumer Healthcare Inc. (NYSE: PBH) is a leading consumer healthcare company growing trusted, category-defining brands. Headquartered in New York, the Company markets, sells, manufactures and distributes its products across the U.S., Canada, Australia, and select other international markets. Its diverse portfolio of iconic brands includes Breathe Right®, Monistat®, Summer's Eve®, BC®, Goody's®, Dramamine®, Fleet®, Hydralyte®, Gaviscon®, DenTek®, TheraTears®, Clear Eyes®, Compound W®, Dermal Therapy®, Chloraseptic®, Luden's®, Little Remedies®, Boudreaux's Butt Paste®, Nix®, and Debrox®, among others. Learn more at www.prestigeconsumerhealthcare.com.

Prestige Consumer Healthcare Inc.

Condensed Consolidated Statements of Income and Comprehensive Income

(Unaudited)

Three Months Ended September 30, Six Months Ended September 30,

(In thousands, except per share data) 2026 2025 2026 2025

Total Revenues $ 336,307 $ 274,114 $ 602,017 $ 523,644

Cost of Sales

Cost of sales excluding depreciation 160,512 120,043 286,978 226,758

Cost of sales depreciation 3,257 2,492 6,313 4,976

Cost of sales 163,769 122,535 293,291 231,734

Gross profit 172,538 151,579 308,726 291,910

Operating Expenses

Advertising and marketing 52,226 38,701 86,894 73,638

General and administrative 30,893 28,037 74,196 56,493

Depreciation and amortization 8,707 5,171 14,404 10,353

Total operating expenses 91,826 71,909 175,494 140,484

Operating income 80,712 79,670 133,232 151,426

Other expense

Interest expense, net 30,026 10,036 43,971 20,239

Loss on extinguishment of debt 1,360 — 1,360 —

Other expense, net 1,876 501 1,910 277

Total other expense, net 33,262 10,537 47,241 20,516

Income before income taxes 47,450 69,133 85,991 130,910

Provision for income taxes 22,155 26,922 31,519 41,233

Net income $ 25,295 $ 42,211 $ 54,472 $ 89,677

Earnings per share:

Basic $ 0.53 $ 0.86 $ 1.15 $ 1.82

Diluted $ 0.53 $ 0.86 $ 1.14 $ 1.81

Weighted average shares outstanding:

Basic 47,495 49,025 47,479 49,249

Diluted 47,593 49,264 47,599 49,547

Comprehensive income, net of tax:

Currency translation adjustments 1,352 655 42 6,059

Total other comprehensive income 1,352 655 42 6,059

Comprehensive income $ 26,647 $ 42,866 $ 54,514 $ 95,736

Prestige Consumer Healthcare Inc.

Condensed Consolidated Balance Sheets

(Unaudited)

(In thousands)

September 30, 2026 March 31, 2026

Assets

Current assets

Cash and cash equivalents $ 46,515 $ 63,868

Accounts receivable, net of allowance of $24,135 and $18,187, respectively

244,124 191,920

Inventories 179,203 159,132

Prepaid expenses and other current assets 22,286 16,564

Total current assets 492,128 431,484

Property, plant and equipment, net 116,868 121,689

Operating lease right-of-use assets 24,621 27,780

Finance lease right-of-use assets, net 20,136 21,776

Goodwill 705,264 581,109

Intangible assets, net 3,357,059 2,299,605

Other long-term assets 5,585 10,870

Total Assets $ 4,721,661 $ 3,494,313

Liabilities and Stockholders' Equity

Current liabilities

Accounts payable $ 44,020 $ 22,791

Accrued interest payable 16,528 15,578

Operating lease liabilities, current portion 7,218 6,910

Finance lease liabilities, current portion 2,743 2,656

Other accrued liabilities 97,994 72,989

Total current liabilities 168,503 120,924

Long-term debt, net 2,079,324 993,953

Deferred income tax liabilities 489,533 447,417

Long-term operating lease liabilities, net of current portion 17,509 20,955

Long-term finance lease liabilities, net of current portion 16,576 17,968

Other long-term liabilities 5,551 5,580

Total Liabilities 2,776,996 1,606,797

Total Stockholders' Equity 1,944,665 1,887,516

Total Liabilities and Stockholders' Equity $ 4,721,661 $ 3,494,313

Prestige Consumer Healthcare Inc.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

Six Months Ended September 30,

(In thousands) 2026 2025

Operating Activities

Net income $ 54,472 $ 89,677

Adjustments to reconcile net income to net cash provided by operating activities:

Depreciation and amortization 20,717 15,329

Loss on disposal of property and equipment 333 131

Deferred and other income taxes 15,460 23,211

Amortization of debt origination costs 2,109 889

Amortization of acquired inventory step-up 17,207 —

Stock-based compensation costs 5,225 5,449

Loss on extinguishment of debt 1,360 —

Non-cash operating lease cost 4,192 3,879

Changes in operating assets and liabilities, net of the effects of acquisitions:

Accounts receivable (45,392) (2,580)

Inventories 3,566 (10,277)

Prepaid expenses and other current assets (6,181) (11,767)

Accounts payable 16,023 22,545

Accrued liabilities 24,003 3,923

Operating lease liabilities (4,185) (3,839)

Other (256) (71)

Net cash provided by operating activities 108,653 136,499

Investing Activities

Purchases of property, plant and equipment (7,327) (2,940)

Acquisitions, net of cash acquired (1,193,557) —

Other (1,757) (1,927)

Net cash (used in) investing activities (1,202,641) (4,867)

Financing Activities

Proceeds from issuance of Term Loan 1,140,000 —

Net increase in line of credit 887 —

Term loan repayments (30,000) —

Proceeds from issuance of senior notes 400,000 —

Repayment of senior notes (400,000) —

Payments of debt issuance costs (28,829) —

Payments of finance leases (1,231) (1,147)

Proceeds from exercise of stock options 94 3,907

Fair value of shares surrendered as payment of tax withholding (2,684) (4,216)

Repurchase of common stock — (109,775)

Other (1,486) —

Net cash provided by (used in) financing activities 1,076,751 (111,231)

Effects of exchange rate changes on cash and cash equivalents (116) 821

(Decrease) increase in cash and cash equivalents (17,353) 21,222

Cash and cash equivalents - beginning of period 63,868 97,884

Cash and cash equivalents - end of period $ 46,515 $ 119,106

Interest paid $ 41,124 $ 21,879

Income taxes paid $ 24,027 $ 25,088

Prestige Consumer Healthcare Inc.

Condensed Consolidated Statements of Income

Business Segments

(Unaudited)

Three Months Ended September 30, 2026

(In thousands) North American OTC Healthcare International OTC Healthcare Consolidated

Total segment revenues* $ 271,812 $ 64,495 $ 336,307

Cost of sales 132,992 30,777 163,769

Gross profit 138,820 33,718 172,538

Advertising and marketing 40,488 11,738 52,226

Contribution margin $ 98,332 $ 21,980 $ 120,312

Other operating expenses 39,600

Operating income $ 80,712

*Intersegment revenues of $0.9 million were eliminated from the North American OTC Healthcare segment.

Six Months Ended September 30, 2026

(In thousands) North American OTC Healthcare International OTC Healthcare Consolidated

Total segment revenues* $ 498,018 $ 103,999 $ 602,017

Cost of sales 243,257 50,034 293,291

Gross profit 254,761 53,965 308,726

Advertising and marketing 69,418 17,476 86,894

Contribution margin $ 185,343 $ 36,489 $ 221,832

Other operating expenses 88,600

Operating income $ 133,232

*Intersegment revenues of $1.6 million were eliminated from the North American OTC Healthcare segment.

Three Months Ended September 30, 2025

(In thousands) North American OTC Healthcare International OTC Healthcare Consolidated

Total segment revenues* $ 230,756 $ 43,358 $ 274,114

Cost of sales 102,348 20,187 122,535

Gross profit 128,408 23,171 151,579

Advertising and marketing 32,033 6,668 38,701

Contribution margin $ 96,375 $ 16,503 $ 112,878

Other operating expenses 33,208

Operating income $ 79,670

*Intersegment revenues of $0.6 million were eliminated from the North American OTC Healthcare segment.

Six Months Ended September 30, 2025

(In thousands) North American OTC Healthcare International OTC Healthcare Consolidated

Total segment revenues* $ 443,334 $ 80,310 $ 523,644

Cost of sales 194,526 37,208 231,734

Gross profit 248,808 43,102 291,910

Advertising and marketing 60,987 12,651 73,638

Contribution margin $ 187,821 $ 30,451 $ 218,272

Other operating expenses 66,846

Operating income $ 151,426

* Intersegment revenues of $1.2 million were eliminated from the North American OTC Healthcare segment.

About Non-GAAP Financial Measures

In addition to financial results reported in accordance with GAAP, we disclose certain Non-GAAP financial measures ("NGFMs"), including, but not limited to, Non-GAAP Organic Revenues, Non-GAAP Organic Revenue Change Percentage, Non-GAAP Adjusted Gross Margin, Non-GAAP Adjusted Gross Margin Percentage, Non-GAAP Adjusted General and Administrative Expense, Non-GAAP Adjusted General and Administrative Expense Percentage, Non-GAAP EBITDA, Non-GAAP EBITDA Margin, Non-GAAP Adjusted EBITDA, Non-GAAP Adjusted EBITDA Margin, Non-GAAP Adjusted Net Income, Non-GAAP Adjusted Diluted EPS, Non-GAAP Free Cash Flow, Non-GAAP Adjusted Free Cash Flow, and Net Debt. We use these NGFMs internally, along with GAAP information, in evaluating our operating performance and in making financial and operational decisions. We believe that the presentation of these NGFMs provides investors with greater transparency, and provides a more complete understanding of our business than could be obtained absent these disclosures, because the supplemental data relating to our financial condition and results of operations provides additional ways to view our operation when considered with both our GAAP results and the reconciliations below. In addition, we believe that the presentation of each of these NGFMs is useful to investors for period-to-period comparisons of results in assessing shareholder value, and we use these NGFMs internally to evaluate the performance of our personnel and also to evaluate our operating performance and compare our performance to that of our competitors.

These NGFMs are not in accordance with GAAP, should not be considered as a measure of profitability or liquidity, and may not be directly comparable to similarly titled NGFMs reported by other companies. These NGFMs have limitations and they should not be considered in isolation from or as an alternative to their most closely related GAAP measures reconciled below. Investors should not rely on any single financial measure when evaluating our business. We recommend investors review the GAAP financial measures included in this earnings release. When viewed in conjunction with our GAAP results and the reconciliations below, we believe these NGFMs provide greater transparency and a more complete understanding of factors affecting our business than GAAP measures alone.

NGFMs Defined

We define our NGFMs presented herein as follows:

•Non-GAAP Organic Revenues: GAAP Total Revenues excluding revenues associated with acquisitions and the impact of foreign currency exchange rates in the periods presented.

•Non-GAAP Organic Revenue Change Percentage: Calculated as the change in Non-GAAP Organic Revenues from prior year divided by prior year Non-GAAP Organic Revenues.

•Non-GAAP Adjusted Gross Margin: GAAP Gross Profit minus amortization of inventory fair value step-up, acquired facility remediation, period overhead and idle capacity costs.

•Non-GAAP Adjusted Gross Margin Percentage: Calculated as Non-GAAP Adjusted Gross Margin divided by GAAP Total Revenues.

•Non-GAAP Adjusted General and Administrative Expense: GAAP General and Administrative expenses minus costs associated with acquisitions.

•Non-GAAP Adjusted General and Administrative Expense Percentage: Calculated as Non-GAAP Adjusted General and Administrative expense divided by GAAP Total Revenues.

•Non-GAAP EBITDA: GAAP Net Income before interest expense, net, provision for income taxes, and depreciation and amortization.

•Non-GAAP EBITDA Margin: Calculated as Non-GAAP EBITDA divided by GAAP Total Revenues.

•Non-GAAP Adjusted EBITDA: Non-GAAP EBITDA before amortization of inventory fair value step‑up, acquired facility remediation, period overhead and idle capacity costs, costs associated with acquisitions, and loss on extinguishment of debt.

•Non-GAAP Adjusted EBITDA Margin: Calculated as Non-GAAP adjusted EBITDA divided by GAAP Total Revenues.

•Non-GAAP Adjusted Net Income: GAAP Net Income before amortization of inventory fair value step-up, depreciation of idle assets during remediation period, acquired facility remediation, period overhead and idle capacity costs, costs associated with acquisitions in General and Administrative Expense, loss on extinguishment of debt, applicable tax impact associated with these items and normalized tax rate adjustments.

•Non-GAAP Adjusted Diluted EPS: Calculated as Non-GAAP Adjusted Net Income, divided by the diluted weighted average number of shares outstanding during the period.

•Non-GAAP Free Cash Flow: Calculated as GAAP Net cash provided by operating activities less cash paid for capital expenditures.

•Non-GAAP Adjusted Free Cash Flow: Non-GAAP free cash flow plus acquisition and other costs paid.

•Net Debt: Calculated as total principal amount of debt outstanding ($2,110,000 at September 30, 2026) less cash and cash equivalents ($46,515 at September 30, 2026). Amounts in thousands.

The following tables set forth the reconciliations of each of our NGFMs (other than Net Debt, which is reconciled above) to their most directly comparable financial measures presented in accordance with GAAP.

Reconciliation of GAAP Total Revenues to Non-GAAP Organic Revenues and related Non-GAAP Organic Revenue Change percentage:

Three Months Ended September 30, Six Months Ended September 30,

2026 2025 2026 2025

(In thousands)

GAAP Total Revenues $ 336,307 $ 274,114 $ 602,017 $ 523,644

Revenue Change 22.7 % 15.0 %

Adjustments:

Revenues associated with acquisitions (a) (65,083) — (71,028) —

Impact of foreign currency exchange rates — 1,530 — 3,616

Total adjustments (65,083) 1,530 (71,028) 3,616

Non-GAAP Organic Revenues $ 271,224 $ 275,644 $ 530,989 $ 527,260

Non-GAAP Organic Revenue Change (1.6) % 0.7 %

(a) Revenues associated with our Breathe Right® portfolio and LaCorium Health acquisitions are excluded for purposes of calculating Non-GAAP organic revenues. These revenue adjustments relate to our North America and International OTC Healthcare segments.

Reconciliation of GAAP Gross Profit to Non-GAAP Adjusted Gross Margin and related Non-GAAP Adjusted Gross Margin percentage:

Three Months Ended September 30, Six Months Ended September 30,

2026 2025 2026 2025

(In thousands)

GAAP Total Revenues $ 336,307 $ 274,114 $ 602,017 $ 523,644

GAAP Gross Profit $ 172,538 $ 151,579 $ 308,726 $ 291,910

GAAP Gross Profit as a Percentage of GAAP Total Revenue 51.3 % 55.3 % 51.3 % 55.7 %

Adjustments:

Amortization of inventory fair value step‑up 14,367 — 17,207 —

Acquired facility remediation, period overhead and idle capacity costs (a)

7,079 — 14,227 —

Total adjustments 21,446 — 31,434 —

Non-GAAP Adjusted Gross Margin $ 193,984 $ 151,579 $ 340,160 $ 291,910

Non-GAAP Adjusted Gross Margin as a Percentage of GAAP Total Revenues 57.7 % 55.3 % 56.5 % 55.7 %

(a) Represents manufacturing and administrative overhead incurred during a remediation period following the acquisition of Pillar5, during which production was significantly constrained. As a result, normal overhead absorption levels were not achieved, leading to elevated unit costs. Management believes these costs are not indicative of the Company’s expected ongoing operating cost structure once the facility is fully remediated and operating at normal production levels.

Reconciliation of GAAP General and Administrative Expense and related GAAP General and Administrative Expense percentage to Non-GAAP Adjusted General and Administrative expense and related Non-GAAP Adjusted General and Administrative Expense percentage:

Three Months Ended September 30, Six Months Ended September 30,

2026 2025 2026 2025

(In thousands)

GAAP General and Administrative Expense $ 30,893 $ 28,037 $ 74,196 $ 56,493

GAAP General and Administrative Expense as a Percentage of GAAP Total Revenue 9.2 % 10.2 % 12.3 % 10.8 %

Adjustments:

Costs associated with acquisitions (a) 722 — 13,545 —

Total adjustments 722 — 13,545 —

Non-GAAP Adjusted General and Administrative Expense $ 30,171 $ 28,037 $ 60,651 $ 56,493

Non-GAAP Adjusted General and Administrative Expense Percentage as a Percentage of GAAP Total Revenues 9.0 % 10.2 % 10.1 % 10.8 %

(a) Costs related to the consummation of the acquisition process such as legal and other acquisition-related professional fees.

Reconciliation of GAAP Net Income to Non-GAAP EBITDA and related Non-GAAP EBITDA Margin, Non-GAAP Adjusted EBITDA and related Non-GAAP Adjusted EBITDA Margin:

Three Months Ended September 30, Six Months Ended September 30,

2026 2025 2026 2025

(In thousands)

GAAP Net Income $ 25,295 $ 42,211 $ 54,472 $ 89,677

Interest expense, net 30,026 10,036 43,971 20,239

Provision for income taxes 22,155 26,922 31,519 41,233

Depreciation and amortization 11,964 7,663 20,717 15,329

Non-GAAP EBITDA $ 89,440 $ 86,832 $ 150,679 $ 166,478

Non-GAAP EBITDA Margin 26.6 % 31.7 % 25.0 % 31.8 %

Adjustments:

Amortization of inventory fair value step‑up 14,367 — 17,207 —

Acquired facility remediation, period overhead and idle capacity costs (a)

7,079 — 14,227 —

Costs associated with acquisitions in G&A (b)

722 — 13,545 —

Loss on extinguishment of debt 1,360 — 1,360 —

Total adjustments 23,528 — 46,339 —

Non-GAAP Adjusted EBITDA $ 112,968 $ 86,832 $ 197,018 $ 166,478

Non-GAAP Adjusted EBITDA Margin 33.6 % 31.7 % 32.7 % 31.8 %

(b) Costs related to the consummation of the acquisition process such as legal and other acquisition-related professional fees.

Reconciliation of GAAP Net Income and GAAP Diluted Earnings Per Share to Non-GAAP Adjusted Net Income and related Non-GAAP Adjusted Diluted Earnings Per Share:

Three Months Ended September 30, Six Months Ended September 30,

2026 2026 Diluted EPS 2025 2025 Diluted EPS 2026 2026 Diluted EPS 2025 2025 Diluted EPS

(In thousands, except per share data)

GAAP Net Income and Diluted EPS 25,295 $ 0.53 42,211 $ 0.86 54,472 $ 1.14 89,677 $ 1.81

Adjustments:

Amortization of inventory fair value step‑up 14,367 0.30 — — 17,207 0.36 — —

Depreciation of idle assets during remediation period (a) 71 — — — 141 — — —

Acquired facility remediation, period overhead and idle capacity costs (b) 7,079 0.15 — — 14,227 0.30 — —

Costs associated with acquisitions in General and Administrative Expense (c) 722 0.02 — — 13,545 0.28 — —

Loss on extinguishment of debt 1,360 0.03 — — 1,360 0.03 — —

Tax impact of adjustments (d) (5,741) (0.12) — — (11,300) (0.24) — —

Normalized tax rate adjustments (e) 10,612 0.22 10,261 0.21 10,612 0.22 10,261 0.21

Total adjustments 28,470 0.60 10,261 0.21 45,792 0.95 10,261 0.21

Non-GAAP Adjusted Net Income and Adjusted Diluted EPS $ 53,765 $ 1.13 $ 52,472 $ 1.07 $ 100,264 $ 2.11 $ 99,938 $ 2.02

(a) Represents depreciation expense recorded during the remediation period following the acquisition of Pillar5, during which certain production lines were not operating. Management believes this depreciation is not reflective of expected ongoing depreciation levels once the facility is fully remediated and operating at normal production levels.

(b) Represents manufacturing and administrative overhead incurred during a remediation period following the acquisition of Pillar5, during which production was significantly constrained. As a result, normal overhead absorption levels were not achieved, leading to elevated unit costs. Management believes these costs are not indicative of the Company’s expected ongoing operating cost structure once the facility is fully remediated and operating at normal production levels.

(c) Costs related to the consummation of the acquisition process such as legal and other acquisition-related professional fees.

(d) The income tax adjustments are determined using applicable rates in the taxing jurisdictions in which the above adjustments relate and includes both current and deferred income tax expense (benefit) based on the specific nature of specific Non-GAAP performance measure.

(e) Income tax adjustments to adjust for discrete income tax items.

Note: Amounts may not add due to rounding.

Reconciliation of GAAP Net Income to Non-GAAP Free Cash Flow and Non-GAAP Adjusted Free Cash Flow:

Three Months Ended September 30, Six Months Ended September 30,

2026 2025 2026 2025

(In thousands)

GAAP Net Income $ 25,295 $ 42,211 $ 54,472 $ 89,677

Adjustments:

Adjustments to reconcile net income to net cash provided by operating activities as shown in the Statement of Cash Flows 48,077 29,324 66,603 48,888

Changes in operating assets and liabilities, net of effects of acquisitions as shown in the Statement of Cash Flows (35,507) (14,049) (12,422) (2,066)

Total adjustments 12,570 15,275 54,181 46,822

GAAP Net cash provided by operating activities 37,865 57,486 108,653 136,499

Purchases of property and equipment (3,624) (2,102) (7,327) (2,940)

Non-GAAP Free Cash Flow 34,241 55,384 101,326 133,559

Acquisition and other costs paid 5,000 — 21,664 —

Non-GAAP Adjusted Free Cash Flow $ 39,241 $ 55,384 $ 122,990 $ 133,559

Outlook for Fiscal Year 2027:

Reconciliation of Projected GAAP Net cash provided by operating activities to Projected Non-GAAP Free Cash Flow

and Projected Non-GAAP Adjusted Free Cash Flow:

(In millions)

Projected FY'27 GAAP Net cash provided by operating activities $ 269

Additions to property and equipment for cash (26)

Projected FY'27 Non-GAAP Free Cash Flow 243

Acquisition and other costs paid 22

Projected FY'27 Non-GAAP Adjusted Free Cash Flow $ 265

Reconciliation of Projected GAAP Diluted EPS to Projected Non-GAAP Adjusted Diluted EPS (a):

Low High

Projected FY'27 GAAP Diluted EPS $ 3.53 $ 3.60

Adjustments:

Costs associated with Pillar5 manufacturing optimization and integration 0.30 0.30

Costs associated with acquisitions of the Breathe Right® portfolio and LaCorium Health 0.64 0.64

Loss on extinguishment of debt 0.03 0.03

Tax impact of adjustments and normalized tax rate adjustments (0.02) (0.02)

Total adjustments $ 0.95 $ 0.95

Projected FY'27 Non-GAAP Adjusted Diluted EPS $ 4.48 $ 4.55

(a) The above reconciliation of this forward-looking non-GAAP financial measure only includes adjustments for Q1 and Q2 2027 and does not include additional adjustments for the remainder of fiscal 2027. These future adjustments are highly uncertain, given the significant variability and difficulty in making accurate projections of the adjustments related to the Breathe Right® portfolio and LaCorium Health acquisitions and the costs associated with Pillar5 manufacturing optimization and integration. As a result, the Company is unable to quantify those future adjustments, which are likely significant, without unreasonable efforts.

EX-99.2

Filename: exhibit992pbh_fy27xq2.htm · Sequence: 3

exhibit992pbh_fy27xq2

Second Quarter FY 2027 Results November 5th, 2026 Exhibit 99.2

S E C O N D Q U A R T E R F Y 2 7 R E S U L T S Safe Harbor Disclosure This presentation contains certain “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding the Company’s expected financial performance, including revenues, organic revenue growth, adjusted diluted EPS, gross margin and adjusted free cash flow; the Company’s ability to expand its Clear Eyes® supply and restore the Company’s Eye Care leadership position; stable organic growth across the Company’s portfolio and growth in eCommerce; growth from the Breathe Right® and LaCorium® acquisitions above Company averages; and the Company’s ability to reduce leverage. Words such as “anticipate,” “expect,” “believe,” “target,” “outlook,” “focus,” “set up,” “positioned,” “prioritize,” “on track,” “continue,” “can,” “will,” “may,” “should,” “could,” “would,” and similar expressions identify forward-looking statements. Such forward-looking statements represent the Company’s expectations and beliefs and involve a number of known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those expressed or implied by such forward-looking statements. These factors include, among others, the ability to increase the supply of Clear Eyes® from Pillar5 and other suppliers, including the timing and cost of improvements to the Pillar5 facility; the Company’s ability to comply with regulatory requirements and maintain product quality; the impact of any product recalls; the ability of the Company’s manufacturing operations and third party manufacturers and logistics providers and suppliers to meet demand for its other products and to avoid inflationary cost increases and supply disruption; the Company’s ability to successfully integrate the Breathe Right® and LaCorium® acquisitions and realize anticipated synergies; the Company’s level of indebtedness and changes in interest rates; the impact of economic and business conditions; consumer trends; competitive pressures; the impact of the Company’s advertising and promotional and new product development initiatives; customer inventory management initiatives and ordering patterns; the ability to pass along rising costs to customers without impacting sales; fluctuating foreign exchange rates; evolving U.S. and international tariffs and trade actions; geopolitical instability; and other risks set forth in Part I, Item 1A. Risk Factors in the Company’s Annual Report on Form 10-K for the year ended March 31, 2026 and in subsequent Quarterly Reports on Form 10-Q. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this presentation. Except to the extent required by applicable law, the Company undertakes no obligation to update any forward-looking statement contained in this presentation, whether as a result of new information, future events, or otherwise. All non-GAAP numbers presented are footnoted and reconciled to their closest GAAP measurement in the attached reconciliation schedule and in our November 5, 2026 earnings release in the “About Non-GAAP Financial Measures” section. Footnotes Reference footnotes on certain pages are detailed in the appendix on page 17.

S E C O N D Q U A R T E R F Y 2 7 R E S U L T S I. Performance Highlights

S E C O N D Q U A R T E R F Y 2 7 R E S U L T S Second Quarter Performance Exceeded Expectations ◼ Q2 revenue of $336.3 million, up 22.7% versus prior year — Organic revenue(1) decline of 1.6%, as expected, due to sales timing — First half organic revenue(1) growth of 0.7% — Base business consumption performing well, in-line with expectations ◼ Growth led by TheraTears®, Dramamine®, Compound W®, and Hydralyte® ◼ Breathe Right® and LaCorium® acquisitions off to a good start ◼ Solid adjusted Gross Margin(2) of 57.7% up 240 basis points ◼ Adjusted Diluted EPS(2) of $1.13 versus $1.07 prior year ◼ Financial profile remains solid, with strong Adjusted Free Cash Flow(2) conversion ◼ Closed LaCorium acquisition July 1 ◼ Investing in Pillar5 to unlock long-term eye care capacity ◼ Free Cash Flow priority for balance of the year is reducing leverage Q2 and 1H Sales Highlights Capital Allocation Priorities Superior Earnings and FCF 4

S E C O N D Q U A R T E R F Y 2 7 R E S U L T S ◼ Own nighttime breathing and expand the user base ◼ New marketing campaign that builds on prior success ◼ Invest in adjacent opportunities like Sports ◼ Leverage in-house resources to accelerate innovation, distribution ◼ Operations largely consolidated as of August ◼ Brand tracking to expectations ◼ Main integration to complete by end of Q3 ◼ Further synergies to be captured over 12-18 months Acquisitions on Track; Key Brands Well Positioned for Success Breathe Right® & Dermal Therapy® Positioned for Long-term Brand-Building Integration Proven Foundation Significant Future Opportunities ◼ Iconic brand heritage dating to 1990s ◼ Established international presence ◼ Strong, stable financial profile ◼ Sold in Australia & New Zealand ◼ Brand heritage dating back to 1990s ◼ Wide-ranging efficacy-driven skin care solutions ◼ New marketing efforts that build on prior success ◼ Fuel efficacy-driven innovation ◼ Grow Australian market share across sub-categories ◼ Future geographic expansion opportunity behind Flexitol® 5

S E C O N D Q U A R T E R F Y 2 7 R E S U L T S Ample LaCorium® Opportunities Behind Dermal Therapy® Proven History of Long-term Brand-Building, Generating Sales and Market Share Growth ✓ Extend “It Works” marketing campaign success 70%+ % of Sales Lip Care Foot Care Troubled Skin Hair & Scalp Personal Care Acne Dermal Therapy® Has a History of Category Leadership in Australia #1 Market Share* in Lip Care Unique ultra-moisturizing formulations Plentiful Opportunities for Future Growth ✓ Fuel continued innovation with efficacy-driven launches *IQVIA Pharmacy scan sales 52 weeks ending September 2026 First topical cold sore gel with lysine #3 Market Share* in Foot Care Podiatrist-recommended for need-states Market-first sunscreen for acne-prone skin Unique serum with smart melanin modulation system 6

S E C O N D Q U A R T E R F Y 2 7 R E S U L T S Strong Online Consumption Growth via Strategic Investments 7 ◼ History of consistent consumption performance across eCommerce ◼ Growing market share across strategic brands year-to-date *Year-over-year retail sales as of 10/6/2026 & fiscal year-end FY26 and FY25 Strategic Actions and Continued Investments Driving Success ◼ Engaging page content to drive conversion ◼ Optimize media investment ◼ Lead banner events ◼ Make strategic high-return investments+14%e C o m m erce POS Grow th * vs. 1H FY 26

S E C O N D Q U A R T E R F Y 2 7 R E S U L T S II. Financial Overview

S E C O N D Q U A R T E R F Y 2 7 R E S U L T S Q2 FY 27 Performance Highlights Q2 FY 27 Q2 FY 26 Dollar values in millions, except per share data. $336.3 $113.0 $1.13 $274.1 $86.8 $1.07 Revenue Adj. EBITDA Adj. Diluted EPS 22.7% 30.1% 5.6% Revenue of $336.3 million, up 22.7% vs. prior year Adjusted Diluted EPS(2) of $1.13 up vs. $1.07 adjusted prior year Adjusted EBITDA(2) of $113.0 million, up 30.1% vs. adjusted prior year 9 (2) (2)

S E C O N D Q U A R T E R F Y 2 7 R E S U L T S 3 Months Ended* First Half Comments FY27 Second Quarter and 1H Consolidated Financial Summary ◼ Revenue up 0.7% organically(1) versus prior year, as expected – North America segment up – Double-digit E-Commerce consumption growth – International segment up on an organic basis, including strong Hydralyte® sales – ~$71 million benefit from acquisitions ◼ Adjusted Gross Margin(2) of 56.5% ◼ A&M of 14.4% of Revenue, consistent with expectations and prior year ◼ Adjusted G&A(2) of 10.1% of Revenue ◼ Adjusted Diluted EPS(2) up 4.5% vs. PY 10 6 Months Ended* Dollar values in millions, except per share data. Amounts may not add due to rounding • Adjusted financial metrics presented above are non-GAAP – see footnote (2) of appendix for full descriptions and reconciliations Q2 FY 27 Q2 FY 26 % Chg 2H FY 27 2H FY 26 % Chg Total Revenue 336.3$ 274.1$ 22.7% 602.0$ 523.7$ 15.0% Adjusted Gross Profit 194.0 151.6 28.0% 340.2 291.9 16.5% % Margin 57.7% 55.3% 56.5% 55.7% A&M 52.2 38.7 34.9% 86.9 73.6 18.0% % Total Revenue 15.5% 14.1% 14.4% 14.1% Adjusted G&A 30.2 28.0 7.6% 60.7 56.5 7.4% % Total Revenue 9.0% 10.2% 10.1% 10.8% D&A (ex. COGS D&A) 8.7 5.2 68.4% 14.4 10.4 39.1% Adjusted Operating Income 102.9$ 79.7$ 29.1% 178.2$ 151.4$ 17.7% % Margin 30.6% 29.1% 29.6% 28.9% Adjusted Earnings Per Share 1.13$ 1.07$ 5.6% 2.11$ 2.02$ 4.5% Adjusted EBITDA 113.0$ 86.8$ 30.1% 197.0$ 166.5$ 18.3% % Margin 33.6% 31.7% 32.7% 31.8%

S E C O N D Q U A R T E R F Y 2 7 R E S U L T S Adjusted Free Cash Flow(2) Comments ◼ Total 1H Adjusted Free Cash Flow(2) of $123.0 million down 8% vs. prior year due to working capital timing — Full-year adjusted free cash flow outlook(4) of $265 million or more — Strong business attributes continue to drive Free Cash Flow ◼ Net Debt at September 30 of $2.1 billion(2) following acquisition of LaCorium® on July 1 for ~$150 million — LaCorium® funded with cash on hand and incremental draw of 7-year Term Loan B — Funded $400 million new 8-year unsecured notes in July, replacing previous upcoming maturity ◼ No debt maturities until 2031 ◼ Remain focused on deleveraging for the remainder of fiscal 2027 Industry Leading Free Cash Flow Trends Dollar values in millions 11 $39.2 $123.0 $55.4 $133.6 Free Cash Flow Free Cash Flow Q2 FY 27 Q2 FY 26 1H FY 27 1H FY 26

S E C O N D Q U A R T E R F Y 2 7 R E S U L T S III. The Road Ahead

S E C O N D Q U A R T E R F Y 2 7 R E S U L T S Transition Year Sets Up Future Value Creation Business Remains Well Positioned to Achieve Three-Year Algorithm Outlined in May Maintain marketing investments behind diversified, needs-based portfolio Stable organic growth across strategic brand portfolio Actions Taken in Last Twelve Months … … Result in Favorable FY 28 & Beyond Outlook Strategic eCommerce channel investments focused on driving consumer takeaway Successful integration of Breathe Right® & LaCorium® acquisitions Stabilizing & supporting the strategic acquisition of Pillar5 Continue to grow and win in eCommerce Breathe Right®, LaCorium® targeted to grow above company average Improved Clear Eyes® supply from vertical integration should prove a strategic advantage 13

S E C O N D Q U A R T E R F Y 2 7 R E S U L T S Eye Care Recovery Path Remains Compelling Favorable Category Demand Outlook Iconic, Trusted Brand ◼ 50+ year Clear Eyes® heritage in redness relief ◼ Iconic, highly memorable evolved marketing ◼ History of market share wins prior to supply disruptions Favorable shelf proposition for retailers Rigorous quality oversight to ensure quality product and standards leadership Advantage of internal supply moving forward via Pillar5 acquisition Strengthen supply consistency with improved site management and focused capex 1 2 3 Near-term Strategic Objectives to Restore Clear Eyes® Market Leadership Strong category demand outlook Pricing power given category dynamics Pent-up demand; Limited category-wide supply availability is opportunity 14

S E C O N D Q U A R T E R F Y 2 7 R E S U L T S Updated FY 27 Outlook ◼ Revenues of $1,290 to $1,315 million — Organic growth of approximately 1% to 3% ◼ ~$190 million revenue anticipated from the Breathe Right and LaCorium acquisitions ◼ Revenues of approximately $1,280 to $1,290 million — Organic revenues approximately flat(1), or ~2% growth excluding Clear Eyes ◼ Anticipate lower Clear Eyes® in second half versus prior year ◼ ~$190 million revenue anticipated from the Breathe Right and LaCorium acquisitions ◼ Adjusted Diluted EPS of $4.55 to $4.65(3) ◼ Gross margin just above 57% due to acquisitions ◼ Anticipate G&A leverage via acquisitions ◼ Adjusted Diluted EPS of $4.48 to $4.55(3) ◼ Gross margin just above 57% due to acquisitions ◼ EPS impacted by revenue adjustment & higher interest expense ◼ Adjusted Free Cash Flow(4) of $270 million or more ◼ Prioritizing debt reduction for the balance of fiscal 2027 ◼ Adjusted Free Cash Flow(4) of $265 million or more ◼ Prioritizing debt reduction for the balance of fiscal 2027 Top Line Trends Free Cash Flow EPS 15 Previously-Issued Outlook Current Outlook

S E C O N D Q U A R T E R F Y 2 7 R E S U L T S Appendix

S E C O N D Q U A R T E R F Y 2 7 R E S U L T S Appendix (1) Organic Revenue is a Non-GAAP financial measure and is reconciled to the most closely related GAAP financial measure in the attached Reconciliation Schedules and / or our earnings release dated November 5, 2026 in the “About Non-GAAP Financial Measures” section. (2) Adjusted Gross Profit, Adjusted Gross Margin, Adjusted G&A, Adjusted Operating Income, Adjusted Net Income, Adjusted Diluted EPS, Adjusted EBITDA & EBITDA Margin, Free Cash Flow, Adjusted Free Cash Flow, and Net Debt are Non-GAAP financial measures and are reconciled to their most closely related GAAP financial measures in the attached Reconciliation Schedules and / or in our earnings release dated November 5, 2026 in the “About Non-GAAP Financial Measures” section. (3) Adjusted Diluted EPS for FY 27 is a projected Non-GAAP financial measure, is reconciled to projected GAAP EPS in the attached Reconciliation Schedules and in our earnings release dated November 5, 2026 in the “About Non-GAAP Financial Measures” section and is calculated based on projected EPS adjusted for anticipated costs associated with Pillar5 manufacturing optimization and integration, adjustments relating to the Breathe Right® portfolio and LaCorium acquisitions, and income tax adjustments. (4) Free Cash Flow and Adjusted Free Cash Flow for FY 27 are projected Non-GAAP financial measures, and are reconciled to projected GAAP Net Cash Provided by Operating Activities in the attached Reconciliation Schedules and in our earnings release dated November 5, 2026 in the “About Non-GAAP Financial Measures” section and are calculated based on projected Net Cash Provided by Operating Activities less projected capital expenditures and cash payments associated with acquisitions. 17

S E C O N D Q U A R T E R F Y 2 7 R E S U L T S 18 Reconciliation Schedules Organic Revenue Change (a) Revenues associated with Breathe Right® and LaCorium Health acquisitions are excluded for purposes of calculating Non-GAAP organic revenues. These revenue adjustments relate to our North America and International OTC Healthcare segments. Three Months Ended September 30, Six Months Ended September 30, 2026 2025 2026 2025 (In Thousands) GAAP Total Revenues $336,307 $274,114 $602,017 $523,664 Revenue Change 22.7% 15.0% Adjustments: Revenues associated with acquisitions(a) (65,083) - (71,028) - Impact of foreign currency exchange rates - 1,530 - $3,616 Total adjustments (65,083) 1,530 (71,028) $3,616 Non-GAAP Organic Revenues $271,224 $275,644 $530,989 $527,280 Non-GAAP Organic Revenue Change (1.6%) 0.7%

S E C O N D Q U A R T E R F Y 2 7 R E S U L T S 19 Reconciliation Schedules (Continued) Adjusted G&A Expense (a) Costs related to the consummation of the acquisition process such as legal and other acquisition-related professional fees. Adjusted Gross Margin Three Months Ended September 30, Six Months Ended September 30, 2026 2025 2026 2025 (In thousands) GAAP Total Revenues $336,307 $274,114 $602,017 $523,664 GAAP Gross Profit $172,538 $151,579 $308,726 $291,910 GAAP Gross Profit as a Percentage of GAAP Total Revenue 51.3% 55.3% 51.3% 55.7% Adjustments: Amortization of inventory fair value step-up 14,367 - 17,207 - Acquired facility remediation, period overhead and idle capacity costs (a) 7,079 - 14,227 - Total adjustments 21,446 - 31,434 - Non-GAAP Adjusted Gross Margin $193,984 $151,579 $340,160 $291,910 Non-GAAP Adjusted Gross Margin as a Percentage of GAAP Total Revenues 57.7% 55.3% 56.5% 55.7% (a) Represents manufacturing and administrative overhead incurred during a remediation period following the acquisition of Pillar5, during which production was significantly constrained. Three Months Ended September 30, Six Months Ended September 30, 2026 2025 2026 2025 (In thousands) GAAP General and Administrative Expense $30,893 $28,037 $74,196 $56,493 GAAP General and Administrative Expense as a Percentage of GAAP Total Revenue 9.2% 10.2% 12.3% 10.8% Adjustments: Costs associated with acquisitions (a) 722 - 13,545 - Total adjustments 722 - 13,545 - Non-GAAP Adjusted General and Administrative Expense $30,171 $28,037 $60,651 $56,493Non-GAAP Adjusted General and Administrative Expense Percentage as a Percentage of GAAP Total Revenues 9.0% 10.2% 10.1% 10.8%

S E C O N D Q U A R T E R F Y 2 7 R E S U L T S 20 Reconciliation Schedules (Continued) Adjusted EBITDA and EBITDA Margin (a) Represents manufacturing and administrative overhead incurred during a remediation period following the acquisition of Pillar5, during which production was significantly constrained. (b) Costs related to the consummation of the acquisition process such as legal and other acquisition-related professional fees. Three Months Ended September 30, Six Months Ended September 30, 2026 2025 2026 2025 (In Thousands) GAAP Net Income $25,295 $42,211 $54,472 $89,677 Interest expense, net 30,026 10,036 43,971 20,239 Provision for income taxes 22,155 26,922 31,519 41,233 Depreciation and amortization 11,964 7,663 20,717 15,329 Non-GAAP EBITDA $89,440 $86,832 $150,679 $166,478 Non-GAAP EBITDA Margin 26.6% 31.7% 25.0% 31.8% Adjustments: Amortization of inventory fair value step-up 14,367 - 17,207 - Acquired facility remediation, period overhead and idle capacity costs (a) 7,079 - 14,227 - Costs associated with acquisitions in G&A (b) 722 - 13,545 - Loss on extinguishment of debt 1,360 - 1,360 - Total adjustments 23,528 - 46,339 - Non-GAAP Adjusted EBITDA $112,968 $86,832 $197,018 $166,478 Non-GAAP Adjusted EBITDA Margin 33.6% 31.7% 32.7% 31.8%

S E C O N D Q U A R T E R F Y 2 7 R E S U L T S 21 Reconciliation Schedules (Continued) Adjusted Free Cash Flow Projected Adjusted Free Cash Flow Three Months Ended September 30, Six Months Ended September 30, 2026 2025 2026 2025 (In Thousands) GAAP Net Income $25,295 $42,211 $54,472 $89,677 Adjustments: Adjustments to reconcile net income to net cash provided by operating activities as shown in the Statement of Cash Flows 48,077 29,324 66,603 48,888 Changes in operating assets and liabilities, net of effects of acquisitions as shown in the Statement of Cash Flows (35,507) (14,049) (12,422) (2,066) Total adjustments 12,570 15,275 54,181 46,822 GAAP Net cash provided by operating activities 37,865 57,486 108,653 136,499 Purchases of property and equipment (3,624) (2,102) (7,327) (2,940) Non-GAAP Free Cash Flow 34,241 55,384 101,326 133,559 Acquisition and other costs paid 5,000 - 21,664 - Non-GAAP Adjusted Free Cash Flow $39,241 $55,384 $122,990 $133,559 (in millions) Projected FY'27 GAAP Net cash provided by operating activities 269$ Additions to property and equipment for cash (26) Projected FY'27 Non-GAAP Free Cash Flow 243 Acquisitions and other costs paid 22 Projected FY'27 Non-GAAP Adjusted Free Cash Flow 265$

S E C O N D Q U A R T E R F Y 2 7 R E S U L T S 22 Reconciliation Schedules (Continued) Adjusted Net Income & Adjusted Diluted EPS (a) Represents depreciation expense recorded during the remediation period following the acquisition of Pillar5, during which certain production lines were not operating. Management believes this depreciation is not reflective of expected ongoing depreciation levels once the facility is fully remediated and operating at normal production levels. (b) Represents manufacturing and administrative overhead incurred during a remediation period following the acquisition of Pillar5, during which production was significantly constrained. As a result, normal overhead absorption levels were not achieved, leading to elevated unit costs. Management believes these costs are not indicative of the Company’s expected ongoing operating cost structure once the facility is fully remediated and operating at normal production levels. (c) Costs related to the consummation of the acquisition process such as legal and other acquisition-related professional fees. (d) The income tax adjustments are determined using applicable rates in the taxing jurisdictions in which the above adjustments relate and includes both current and deferred income tax expense (benefit) based on the specific nature of specific Non-GAAP performance measure. (e) Income tax adjustments to adjust for discrete income tax items. Note: Amounts may not add due to rounding. Projected Adjusted Earnings Per Share* * The reconciliation of this forward-looking non-GAAP financial measure only includes adjustments for Q1 and Q2 2027 and does not include additional adjustments for the remainder of fiscal 2027. These future adjustments are highly uncertain, given the significant variability and difficulty in making accurate projections of the adjustments related to the Breathe Right® portfolio and LaCorium Health acquisitions and the costs associated with Pillar5 manufacturing optimization and integration. As a result, the Company is unable to quantify those future adjustments, which are likely significant, without unreasonable efforts. Three Months Ended September 30, Six Months Ended September 30, 2026 2025 2026 2025 Net Income Adjusted EPS Net Income Adjusted EPS Net Income Adjusted EPS Net Income Adjusted EPS (In thousands, except per share data) GAAP Net Income and Diluted EPS $25,295 $0.53 $42,211 $0.86 $54,472 $1.14 $89,677 $1.81 Adjustments: Amortization of inventory fair value step-up 14,367 0.30 - - 17,207 0.36 - - Depreciation of idle assets during remediation period (a) 71 0.00 - - 141 0.00 - - Acquired facility remediation, period overhead and idle capacity costs (b) 7,079 0.15 - - 14,227 0.30 - - Costs associated with acquisition in General and Administrative Expense (c) 722 0.02 - - 13,545 0.28 - - Loss on extinguishment of debt 1,360 0.03 - - 1,360 0.03 - - Tax impact of adjustments (d) (5,741) (0.12) - - (11,300) (0.24) - - Normalized tax rate adjustment (e) 10,612 0.22 10,261 0.21 10,612 0.22 10,261 0.21 Total Adjustments 28,470 0.60 10,261 0.21 45,792 0.95 10,261 0.21 Non-GAAP Adjusted Net Income and Adjusted EPS $53,765 $1.13 $52,472 $1.07 $100,264 $2.11 $99,938 $2.02 Low High Projected FY'27 GAAP Diluted EPS 3.53$ 3.60$ Adjustments: Costs associated with Pillar5 manufacturing optimization and integration 0.30 0.30 Costs associated with acquisitions of the Breathe Right & LaCorium portfolios 0.64 0.64 Loss on extinguishment of debt 0.03 0.03 Tax impact of adjustments and normalized tax rate adjustment (0.02) (0.02) Total adjustments 0.95 0.95 Projected FY'27 Non-GAAP Adjusted Diluted EPS 4.48$ 4.55$

P C H C O N F I D E N T I A L A N D P R O P R I E T A R Y I N F O R M A T I O N

GRAPHIC

Filename: exhibit992pbh_fy27xq2001.jpg · Sequence: 7

Binary file (150244 bytes)

Download exhibit992pbh_fy27xq2001.jpg

GRAPHIC

Filename: exhibit992pbh_fy27xq2002.jpg · Sequence: 8

Binary file (213317 bytes)

Download exhibit992pbh_fy27xq2002.jpg

GRAPHIC

Filename: exhibit992pbh_fy27xq2003.jpg · Sequence: 9

Binary file (43577 bytes)

Download exhibit992pbh_fy27xq2003.jpg

GRAPHIC

Filename: exhibit992pbh_fy27xq2004.jpg · Sequence: 10

Binary file (121215 bytes)

Download exhibit992pbh_fy27xq2004.jpg

GRAPHIC

Filename: exhibit992pbh_fy27xq2005.jpg · Sequence: 11

Binary file (129021 bytes)

Download exhibit992pbh_fy27xq2005.jpg

GRAPHIC

Filename: exhibit992pbh_fy27xq2006.jpg · Sequence: 12

Binary file (143794 bytes)

Download exhibit992pbh_fy27xq2006.jpg

GRAPHIC

Filename: exhibit992pbh_fy27xq2007.jpg · Sequence: 13

Binary file (150023 bytes)

Download exhibit992pbh_fy27xq2007.jpg

GRAPHIC

Filename: exhibit992pbh_fy27xq2008.jpg · Sequence: 14

Binary file (41526 bytes)

Download exhibit992pbh_fy27xq2008.jpg

GRAPHIC

Filename: exhibit992pbh_fy27xq2009.jpg · Sequence: 15

Binary file (86587 bytes)

Download exhibit992pbh_fy27xq2009.jpg

GRAPHIC

Filename: exhibit992pbh_fy27xq2010.jpg · Sequence: 16

Binary file (154858 bytes)

Download exhibit992pbh_fy27xq2010.jpg

GRAPHIC

Filename: exhibit992pbh_fy27xq2011.jpg · Sequence: 17

Binary file (110120 bytes)

Download exhibit992pbh_fy27xq2011.jpg

GRAPHIC

Filename: exhibit992pbh_fy27xq2012.jpg · Sequence: 18

Binary file (39483 bytes)

Download exhibit992pbh_fy27xq2012.jpg

GRAPHIC

Filename: exhibit992pbh_fy27xq2013.jpg · Sequence: 19

Binary file (140142 bytes)

Download exhibit992pbh_fy27xq2013.jpg

GRAPHIC

Filename: exhibit992pbh_fy27xq2014.jpg · Sequence: 20

Binary file (125778 bytes)

Download exhibit992pbh_fy27xq2014.jpg

GRAPHIC

Filename: exhibit992pbh_fy27xq2015.jpg · Sequence: 21

Binary file (112916 bytes)

Download exhibit992pbh_fy27xq2015.jpg

GRAPHIC

Filename: exhibit992pbh_fy27xq2016.jpg · Sequence: 22

Binary file (34734 bytes)

Download exhibit992pbh_fy27xq2016.jpg

GRAPHIC

Filename: exhibit992pbh_fy27xq2017.jpg · Sequence: 23

Binary file (142098 bytes)

Download exhibit992pbh_fy27xq2017.jpg

GRAPHIC

Filename: exhibit992pbh_fy27xq2018.jpg · Sequence: 24

Binary file (83513 bytes)

Download exhibit992pbh_fy27xq2018.jpg

GRAPHIC

Filename: exhibit992pbh_fy27xq2019.jpg · Sequence: 25

Binary file (133957 bytes)

Download exhibit992pbh_fy27xq2019.jpg

GRAPHIC

Filename: exhibit992pbh_fy27xq2020.jpg · Sequence: 26

Binary file (112776 bytes)

Download exhibit992pbh_fy27xq2020.jpg

GRAPHIC

Filename: exhibit992pbh_fy27xq2021.jpg · Sequence: 27

Binary file (119610 bytes)

Download exhibit992pbh_fy27xq2021.jpg

GRAPHIC

Filename: exhibit992pbh_fy27xq2022.jpg · Sequence: 28

Binary file (186033 bytes)

Download exhibit992pbh_fy27xq2022.jpg

GRAPHIC

Filename: exhibit992pbh_fy27xq2023.jpg · Sequence: 29

Binary file (36892 bytes)

Download exhibit992pbh_fy27xq2023.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 31

v3.26.3

Cover

Nov. 05, 2026

Cover [Abstract]

Document Type

8-K

Document Period End Date

Nov. 05, 2026

Entity Registrant Name

PRESTIGE CONSUMER HEALTHCARE INC.

Entity Central Index Key

0001295947

Amendment Flag

false

Entity Incorporation, State or Country Code

Entity File Number

001-32433

Entity Tax Identification Number

20-1297589

Entity Address, Address Line One

660 White Plains Road

Entity Address, City or Town

Tarrytown

Entity Address, State or Province

Entity Address, Postal Zip Code

10591

City Area Code

914

Local Phone Number

524-6800

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common stock, par value $0.01 per share

Trading Symbol

PBH

Security Exchange Name

NYSE

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration